Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says

MT Newswires Live07-01 23:23

Oruka Therapeutics (ORKA) could further de-risk its lead psoriasis drug candidate, ORKA-001, with H2 data expected to show stronger 28-week efficacy than its earlier results and AbbVie's (ABBV) Skyrizi, UBS Securities said in a Wednesday note.

The firm said psoriasis treatments typically show improving efficacy over time. It expects ORKA-001's PASI100 response rate to increase from about 63% at week 16 to 70% to 80% at week 28.

UBS said initial one-year durability data should provide an early indication of ORKA-001's potential for six-month or annual dosing. The firm expects the update in late Q3 or Q4, giving the company more time to include one-year data from additional patients.

The investment firm also said AbbVie's planned acquisition of Apogee Therapeutics (APGE) validates the underlying YTE platform used by ORKA-001 and eases concerns about the intellectual property landscape.

UBS maintained its buy rating on Oruka and raised its price target to $130 from $100.

Price: 94.44, Change: -0.73, Percent Change: -0.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment